CDK9 and glioblastoma: Knockdown of CDK9 or selective CDK9 inhibitors reduced YTHDF2 expression levels in glioblastoma stem cells [69], consistent with our findings (Fig. 4G, Supplementary Material 3: Fig. S3E).